Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Extension CombiRx data show no benefit of combined MS drugs
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Focal vibration in neurorehabilitation.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Dilantin
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Genzyme provides update on U.S. LEMTRADA™ filing
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Antioxidant properties of the triaminopyridine, flupirtine.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Power estimation for non-standardized multisite studies.
Chemotherapeutics in the treatment of multiple sclerosis.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis

Pages